aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Ikena Oncology is a targeted oncology company dedicated to developing novel cancer therapies that address key signaling pathways responsible for cancer growth and metastasis. The company's mission is to redefine the oncology landscape by creating differentiated therapies that target nodes of cancer growth, spread, and therapeutic resistance. Ikena envisions a world where every cancer patient has access to a cure, leveraging its institutional knowledge and advanced tools to develop the right drug using the right modality.
Ikena Oncology has made significant strides in the field of targeted cancer therapies, contributing to the advancement of treatments that offer hope to patients with limited options. The company's innovative approach and commitment to addressing unmet medical needs have positioned it as a leader in the oncology sector. Through strategic collaborations and a dedicated team of experts, Ikena continues to push the boundaries of cancer treatment, aiming to make a lasting impact on patient outcomes.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Ikena Oncology founded?
Ikena Oncology was founded in 2016.
Where is Ikena Oncology's headquarters located?
Ikena Oncology's headquarters is located in Boston, MA, US.
When was Ikena Oncology's last funding round?
Ikena Oncology's most recent funding round was for $40M (USD) in May 2023.
How many employees does Ikena Oncology have?
Ikena Oncology has 68 employees as of Feb 6, 2024.
How much has Ikena Oncology raised to-date?
As of July 05, 2023, Ikena Oncology has raised a total of $209M (USD) since May 15, 2023.
Add Comparison
Total Raised to Date
$209M
USD
Last Update May 15, 2023
Last Deal Details
$40M
USD
May 15, 2023
Post Ipo Equity
Total Employees Over Time
68
As of Feb 2024
Ikena Oncology Address
50 Northern Avenue
Boston,
Massachusetts
02210
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts